T1	Participants 424 597	patients undergoing inguinal herniorrhaphy who receive a COX-2 selective nonsteroidal anti-inflammatory drug (COX-2) or placebo preoperatively and for 4 days postoperatively
T2	Participants 1338 1357	Fifty-five subjects
